The prognostic value of aspartate beta-hydroxylase in early breast cancer. Issue 3 (September 2022)

• Record Type: Journal Article
• Authors: Barboro, Paola; Rubagotti, Alessandra; Poddine, Silvia; Grillo, Federica; Mastracci, Luca; Boccardo, Francesco
• Is Part Of: International journal of biological markers. Volume 37:Issue 3(2022)
• Page Start: 328
• Page End: 335
• Publication Date: 2022-09
• Subjects: ASPH -- breast cancer -- clinical-pathological features -- prognostic biomarkers; Cell receptors -- Periodicals; Histochemistry -- Periodicals; Tumor markers -- Periodicals; Tumor antigens -- Periodicals; 616.99407582
• DOI: 10.1177/03936155221108412
• Languages: English
• ISSNs: 0393-6155

Abstract

Purpose: Aspartate beta-hydroxylase (ASPH) is a transmembrane protein involved in cancer progression, which has been shown to imply a worse prognosis in several solid tumors. The aim of the present study was to further investigate the prognostic value of ASPH in early breast cancer. Methods: ASPH expression was investigated through immunohistochemistry in a cohort of 153 breast cancer patients with long-term follow-up, and correlated with clinical–pathological features plus all-cause and breast-cancer-specific mortality. Appropriate statistics were utilized. Results: ASPH negatively correlated with all-cause and breast-cancer-specific mortality. Conclusions: The results of this cohort study support the prognostic value of ASPH in early breast cancer.